

WHAT IS CLAIMED IS:

1. A method of increasing bone mass or ameliorating loss of bone mass in a patient in need thereof, said method comprising administering to said patient an amount of a complex comprising an IGFII polypeptide and an IGFBP2 polypeptide effective to increase bone mass or ameliorate loss of bone mass in said patient.
2. The method of claim 1, wherein said IGFBP2 polypeptide is full-length IGFBP2.
3. The method of claim 1, wherein said IGFII polypeptide is human IGFII.
4. The method of claim 1, wherein said patient is an osteoporosis patient.
5. The method of claim 1, wherein said complex is administered parenterally.
6. The method of claim 5, wherein said complex is administered intravenously, subcutaneously, intramuscularly, or intranasally.
7. The method of claim 5, wherein said complex is administered via an implanted device.
8. The method of claim 7, wherein said implanted device is an osmotic pump.
9. The method of claim 1, wherein said complex is administered to a mucous membrane.
10. The method of claim 1, wherein said IGFII polypeptide is IGFIIE.
11. A method of targeting a compound to skeletal extracellular matrix of a patient comprising administering a complex to said patient, wherein said complex comprises an IGFII polypeptide, an IGFBP2 polypeptide, and said compound.

12. The method of claim 11, wherein said IGFBP2 polypeptide is full-length IGFBP2.

13. The method of claim 11, wherein said compound comprises a chemotherapeutic agent.

14. The method of claim 11, wherein said compound comprises a growth factor.

15. The method of claim 11, wherein said IGFII polypeptide is IGFIIIE.

16. The method of claim 11, wherein said IGFII polypeptide is human IGFII.

17. The method of claim 14, wherein said growth factor is IGFI.

18. A pharmaceutical composition comprising a complex of IGFII polypeptide and IGFBP2 polypeptide in an amount effective to increase bone mass or ameliorate loss of bone mass in a mammal, and a pharmaceutically acceptable carrier.

19. The composition of claim 18, wherein said IGFII polypeptide is human IGFII.

20. An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises a complex comprising an IGFII polypeptide and an IGFBP2 polypeptide and is therapeutically effective for increasing bone mass or ameliorating loss of bone mass, and wherein the packaging material comprises a label or package insert indicating that said pharmaceutical agent can be used for increasing bone mass or ameliorating loss of bone mass.

21. A method of increasing bone mass or ameliorating loss of bone mass in a patient in need thereof, said method comprising administering to said patient an amount of an IGFII polypeptide and an amount of an IGFBP2 polypeptide effective to increase bone mass or ameliorate loss of bone mass in said patient.

22. The method of claim 21, wherein said IGFII and IGFBP2 polypeptides are in a complex.

23. The method of claim 21, wherein said IGFII and IGFBP2 polypeptides are co-administered.

24. The method of claim 21, wherein said IGFII and IGFBP2 polypeptides are administered separately.

25. The method of claim 21, wherein said IGFII polypeptide is human IGFII.

26. The method of claim 21, wherein said IGFII polypeptide is IGFIII.

27. The method of claim 21, wherein said patient is an osteoporosis patient.

28. The method of claim 21, wherein said IGFII and IGFBP2 polypeptides are administered parenterally.

29. The method of claim 28, wherein said IGFII and IGFBP2 polypeptides are administered intravenously, subcutaneously, intramuscularly, or intranasally.

30. The method of claim 21, wherein said IGFII and IGFBP2 polypeptides are administered via an implanted device.

31. The method of claim 30, wherein said implanted device is an osmotic pump.

32. The method of claim 21, wherein said IGFII and IGFBP2 polypeptides are administered to a mucous membrane.

33. A pharmaceutical composition comprising IGFII polypeptide and IGFBP2 polypeptide in amounts effective to increase bone mass or ameliorate loss of bone mass in a mammal, and a pharmaceutically acceptable carrier.

34. The composition of claim 33, wherein said IGFII polypeptide is human IGFII.

35. The composition of claim 33, wherein said IGFII polypeptide is IGFIIIE.

36. An article of manufacture comprising packaging material and pharmaceutical agents contained within said packaging material, wherein said pharmaceutical agents comprise an IGFII polypeptide and an IGFBP2 polypeptide and are therapeutically effective for increasing bone mass or ameliorating loss of bone mass, and wherein said packaging material comprises a label or package insert indicating that said pharmaceutical agents can be used for increasing bone mass or ameliorating loss of bone mass.

37. A method of targeting an IGFII polypeptide to the skeletal extracellular matrix of a patient, said method comprising administering a composition comprising an IGFII polypeptide and an IGFBP2 polypeptide.